Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 8,375 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 2 Interventional Results available

The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome

NCT03452189
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT01681121
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

NCT03824678
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of S-309309 in Obese Adults

NCT05925114
View directory record Official record
Conditions
Obesity
Interventions
S-309309, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

NCT01215747
View directory record Official record
Conditions
Amyloidosis
Interventions
KIACTA (eprodisate disodium), Placebo
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Glendale, California • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 22, 2026, 7:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917
View directory record Official record
Conditions
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions
AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 7:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Smartphone Ophthalmoscope of Lens Vascularity to Estimate Gestational Age

NCT02346214
View directory record Official record
Conditions
Gestational Age
Interventions
Not listed
Lead sponsor
RTI International
Other
Eligibility
Up to 24 Hours
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Loma Linda, California • Iowa City, Iowa • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 2 Interventional Results available

Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study

NCT01321606
View directory record Official record
Conditions
Anti-biotic Resistance
Interventions
Lactobacillus rhamnosus HN001, sugar pill (placebo)
Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

NCT04441255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

NCT00452335
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 7:11 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Endothelin Receptor Function and Acute Stress

NCT02116335
View directory record Official record
Conditions
Hypertension
Interventions
Bosentan, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 3 Interventional Results available

NVA237 BID Versus Placebo Twelve-week Efficacy Study

NCT01715298
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
59
States / cities
*See Various Dept.'s*, Arizona • Chandler, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

NCT01556763
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions
EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 2 Interventional

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

NCT00810147
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-708163, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 90 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

NCT02039947
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 22, 2026, 7:11 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05954988
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
LTI-03, Placebo
Drug
Lead sponsor
Rein Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 22, 2026, 7:11 PM EDT
Recruiting Phase 2 Interventional

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

NCT07453069
View directory record Official record
Conditions
Vaginal Dysbiosis
Interventions
FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline)
Drug · Other
Lead sponsor
Freya Biosciences ApS
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Not applicable Interventional Results available

The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers

NCT00633256
View directory record Official record
Conditions
Smoking
Interventions
Cycloserine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 22, 2026, 7:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine HCl/Naloxone HCl
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Microtracer [14C]ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients

NCT01733212
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ginger, Placebo Oral Tablet
Drug
Lead sponsor
Joel Yarmush
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 22, 2026, 7:11 PM EDT
Recruiting Phase 2 Interventional

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

NCT07111065
View directory record Official record
Conditions
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Interventions
FISH OIL 500MG OMEGA-3 SOFT GEL MINIS, Placebo
Dietary Supplement
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 7:11 PM EDT
Completed Not applicable Interventional

Rice Bran Supplementation in Treated HIV Infection

NCT02922907
View directory record Official record
Conditions
Inflammation in HIV Infection
Interventions
arabinoxylan rice bran, Placebo for arabinoxylan rice bran
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 22, 2026, 7:11 PM EDT